In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults aged 50 and older, the first flu shot in history built on the same messenger-RNA platform that powered the COVID-19 response. It is, by Moderna's own count, the company's fourth approved U.S. product, joining Spikevax, mNEXSPIKE, and mRESVIA on pharmacy shelves.
That's a headline. But the more interesting story sits underneath it: mRNA technology, once treated as a pandemic-era emergency tool, is now being asked to prove itself in the far less forgiving world of routine, seasonal, annually repeated vaccination. Flu shots don't get emergency author...
